BCG Medium Profitability

DrugCo

ProHub Comment

This is an interviewee-led case that requires diagnostic thinking to identify that the client has inverted approval rates compared to industry peers. The root cause is lax early-stage approval standards leading to more expensive later-stage testing, increasing per-drug costs despite launching the same number of products. The candidate must synthesize this insight and generate creative solutions around operational improvements.

Estimated Time 15 minutes
Difficulty Medium
Source Cornell
50 / 100
Our client is pharmaceutical drug company. The company is less profitable on approved drugs than its peer companies. The client has engaged our team to diagnose the issue and provide a recommendation.

Clarifying Information

  1. Both the client and peer companies (the industry) have the same number of drugs before pre-clinical trial (e.g. 100 drugs).
  2. After testing and approving, the client and the industry launch the same number of drugs.
  3. 100 → 5.4
  4. No material differences between drugs from the client and the industry